Loading organizations...
§ Private Profile · Paris, Ile-de-France, France
clinical-stage biotechnology company developing small-molecule therapies for age-related diseases, focused on sarcopenia and respiratory issues.
Biophytis is a clinical-stage biotechnology company developing small-molecule therapeutics for age-related degenerative diseases, based in Paris, France, with an additional office in Cambridge, Massachusetts. The publicly traded enterprise operates with approximately 22 employees and focuses on treating severe respiratory issues and neuromuscular conditions such as sarcopenia and Duchenne muscular dystrophy. The firm has raised roughly $2.6 million in initial funding and recently secured an agreement with an investor consortium led by Ronghui Renhe Life Technology for up to $20 million to finance Phase 3 clinical trials. Biophytis collaborates with key academic partners like Sorbonne University to advance its lead drug candidate, BIO101, which is currently being evaluated for muscle loss associated with GLP-1 weight-loss therapies. Now trading exclusively on the Euronext Growth Paris exchange, the biotechnology company was founded in 2006 by Stanislas Veillet and René Lafont.
Biophytis has raised $2.6M across 1 funding round.
Biophytis has raised $2.6M in total across 1 funding round.
Biophytis has raised $2.6M across 1 funding round. Most recently, it raised $2.6M Series B in October 2012.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 1, 2012 | $2.6M Series B | — | CM CIC Capital Priv, Metabrain Research, Seventure Partners | Announced |
Biophytis has raised $2.6M in total across 1 funding round.
Biophytis's investors include CM-CIC Capital Priv, Metabrain Research, Seventure Partners.